Are you Dr. Hensold?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
931 Highland Blvd
Ste 3130
Bozeman, MT 59715Phone+1 406-585-5070
Summary
- Dr. Jack Hensold, MD is an oncologist in Bozeman, Montana. He is currently licensed to practice medicine in Montana, Ohio, and Wisconsin. He is affiliated with Bozeman Health Deaconess Regional Medical Center.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1988
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1978 - 1981
Rush Medical College of Rush University Medical CenterClass of 1978
Certifications & Licensure
MT State Medical License 2004 - 2026
OH State Medical License 1988 - 2004
WI State Medical License 1979 - 1981- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
- Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 64 citationsAmerican Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.Nathan A. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Allyn Moushey, Ajjai Alva
Journal of Clinical Oncology. 2021-01-10 - 196 citations15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancersMin Yan, Ronald M. Rerko, Petra Platzer, Dawn M. Dawson, Joseph Willis
Proceedings of the National Academy of Sciences of the United States of America. 2004-12-14 - 1 citationsRevolutionizing Rural Oncology: Innovative Models and Global Perspectives.Rodrigo Munhoz, Sabe Sabesan, Ramya Thota, Janette Merrill, Jack Oliver Hensold
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2024-06-01
Press Mentions
Pilot Program Debuts Infusion Suite at Remote Site, Provides Groundbreaking Opportunity for Rural Communities to Receive Cancer CareOctober 8th, 2024
ACCC Explores Improving Cancer Care Delivery in Rural AreasNovember 20th, 2019
